Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 8Azacitidine 8fludarabine phosphate 6fludarabine 6Peripheral Blood Stem Cell Transplantation 6Whole-Body Irradiation 5Methotrexate 5Cyclosporine 5Busulfan 5Decitabine 4Tacrolimus 3Mycophenolic Acid 3Filgrastim 3Cytarabine 3AP 1903 reagent 3venetoclax 2magrolimab 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2Saline Solution 2Radiotherapy 2Nivolumab 2Cyclosporins 2Biopsy 2Alemtuzumab 2tumor-cells apoptosis factor, human 1sabatolimab 1ponatinib 1plerixafor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Myelodysplastic Syndromes × Sitagliptin Phosphate × Clear all
NCT05895201 2024-04-29

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

Indiana University

Phase 1/2 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡